# Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

> **NCT07677891** · PHASE2 · NOT_YET_RECRUITING · sponsor: **ProGen. Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** PG-102(MG12)
- **DRUG:** Dulaglutide

## Key facts

- **NCT ID:** NCT07677891
- **Lead sponsor:** ProGen. Co., Ltd.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10
- **Primary completion:** 2027-05
- **Final completion:** 2027-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07677891

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07677891, "Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07677891. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*